FibroGen (NASDAQ:FGEN) Releases Earnings Results, Beats Expectations By $0.21 EPS

FibroGen (NASDAQ:FGEN) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21, Zacks reports. The business had revenue of $46.33 million for the quarter, compared to analysts’ expectations of $34.00 million. During the same period in the previous year, the business posted ($0.52) earnings per share.

FibroGen Stock Performance

NASDAQ:FGEN traded down $0.03 during trading hours on Wednesday, reaching $0.36. The stock had a trading volume of 2,529,472 shares, compared to its average volume of 2,225,580. The stock has a 50 day simple moving average of $0.37 and a 200 day simple moving average of $0.72. FibroGen has a 12-month low of $0.29 and a 12-month high of $2.93. The stock has a market cap of $36.15 million, a P/E ratio of -0.30 and a beta of 0.72.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on FGEN shares. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research report on Wednesday. StockNews.com started coverage on FibroGen in a research report on Wednesday, November 6th. They set a “hold” rating for the company.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.